ClinicalTrials.gg
Sign In

Carcinoma, Merkel Cell clinical trials

The registry lists 150 studies for Carcinoma, Merkel Cell across more than 10 countries. 40 are recruiting or about to start. 67 of them are mainly about Carcinoma, Merkel Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Carcinoma, Merkel Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
45
Recruiting
34
Terminated
29
Active, not recruiting
27
Withdrawn
6
Not yet recruiting
5

Phase

Phase 2
83
Phase 1
71
Phase 3
6
Early Phase 1
1

Where

United States
112
Australia
20
France
20
Spain
16
Italy
12
Canada
11

Who runs them

National Cancer Institute (NCI) (11) · Memorial Sloan Kettering Cancer Center (5) · Incyte Corporation (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Fate Therapeutics (4) · Incyte Biosciences International Sàrl (4) · ImmunityBio, Inc. (4) · Fred Hutchinson Cancer Center (4)

What is being tested here

Drugs under test in Carcinoma, Merkel Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pembrolizumab4210
Nivolumab318
pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0213
Cemiplimab202
Ipilimumab105
Retifanlimab103
Prednisone101
Sirolimus101
AMG 757101
Lutetium Lu 177 dotatate101

Drug classes tested here Immune checkpoint inhibitors 10 open · mTOR inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 5

Coming up

4phase 3 studies under way
23studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 34 Carcinoma, Merkel Cell studies recruiting now, 27 (79%) set no upper age limit and 0 (0%) stop at 75 or younger. 5 (15%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 34
AgeWomenMen
104 (12%)4 (12%)
1834 (100%)34 (100%)
3034 (100%)34 (100%)
4034 (100%)34 (100%)
5034 (100%)34 (100%)
6534 (100%)34 (100%)
7534 (100%)34 (100%)
8534 (100%)34 (100%)

Across all 150 studies, recruiting or not: 2% stop at 75 or younger and 0% at 65; 5% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Merkel Cell studies take

Of 33 phase 2 interventional studies under Carcinoma, Merkel Cell, half reached primary completion within 92 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 147 mo36–60 · 25 studies——
Phase 292 mo47–138 · 33 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 150. Browse all 150 → or search them.